全文获取类型
收费全文 | 1884篇 |
免费 | 122篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 11篇 |
儿科学 | 78篇 |
妇产科学 | 31篇 |
基础医学 | 287篇 |
口腔科学 | 78篇 |
临床医学 | 117篇 |
内科学 | 358篇 |
皮肤病学 | 44篇 |
神经病学 | 193篇 |
特种医学 | 423篇 |
外科学 | 160篇 |
综合类 | 40篇 |
预防医学 | 33篇 |
眼科学 | 6篇 |
药学 | 61篇 |
1篇 | |
肿瘤学 | 89篇 |
出版年
2023年 | 7篇 |
2022年 | 7篇 |
2021年 | 7篇 |
2020年 | 10篇 |
2019年 | 6篇 |
2018年 | 13篇 |
2017年 | 17篇 |
2016年 | 16篇 |
2015年 | 17篇 |
2014年 | 33篇 |
2013年 | 48篇 |
2012年 | 35篇 |
2011年 | 51篇 |
2010年 | 46篇 |
2009年 | 62篇 |
2008年 | 59篇 |
2007年 | 75篇 |
2006年 | 63篇 |
2005年 | 50篇 |
2004年 | 40篇 |
2003年 | 43篇 |
2002年 | 22篇 |
2001年 | 40篇 |
2000年 | 25篇 |
1999年 | 34篇 |
1998年 | 84篇 |
1997年 | 86篇 |
1996年 | 80篇 |
1995年 | 71篇 |
1994年 | 44篇 |
1993年 | 62篇 |
1992年 | 22篇 |
1991年 | 26篇 |
1990年 | 36篇 |
1989年 | 70篇 |
1988年 | 66篇 |
1987年 | 64篇 |
1986年 | 72篇 |
1985年 | 89篇 |
1984年 | 45篇 |
1983年 | 33篇 |
1982年 | 29篇 |
1981年 | 32篇 |
1980年 | 38篇 |
1979年 | 8篇 |
1978年 | 27篇 |
1977年 | 28篇 |
1976年 | 21篇 |
1975年 | 22篇 |
1974年 | 6篇 |
排序方式: 共有2010条查询结果,搜索用时 31 毫秒
991.
992.
Antimicrobial potential and gustatory perception of chlorhexidine gluconate mouthwashes with or without alcohol after a single rinse – a randomized controlled crossover clinical trial 下载免费PDF全文
993.
Weisman SJ; Berkow RL; Plautz G; Torres M; McGuire WA; Coates TD; Haak RA; Floyd A; Jersild R; Baehner RL 《Blood》1985,65(3):696-704
Neutrophil function was studied in a patient with polymorphonuclear leukocyte (PMN) glycoprotein-180 deficiency and in her parents. PMNs of the patient had abnormal chemotaxis, phagocytosis, adherence, surface charge, and membrane-associated events of activation. Selective defects to C3b, immunoglobulin G (IgG), phorbol myristate acetate (PMA) and N- formyl-methionyl-leucyl-phenylalanine (FMLP) are described, although C3b receptor density was normal. The parents were found to have abnormal adherence to nylon-wool fibers, abnormal transmembrane potential depolarization with PMA, and reduced amounts of glycoprotein- 180 in their PMNs. These studies provide further evidence that the oxidative burst has several different pathways for activation. They demonstrate that the absence of a single PMN surface glycoprotein is associated with a broad spectrum of PMN functional abnormalities. Finally, the observations made in the parents support an autosomal recessive mode of inheritance. 相似文献
994.
Evaluation of a CD5-specific immunotoxin for treatment of acute graft- versus-host disease after allogeneic marrow transplantation 总被引:3,自引:4,他引:3
Martin PJ; Nelson BJ; Appelbaum FR; Anasetti C; Deeg HJ; Hansen JA; McDonald GB; Nash RA; Sullivan KM; Witherspoon RP; Scannon PJ; Friedmann N; Storb R 《Blood》1996,88(3):824-830
Acute graft-versus-host disease (GVHD) is most often treated with high dose glucocorticoids, but less than half of patients have durable overall improvement. Previous phase I and phase II studies suggested that treatment with a CD5-specific immunotoxin (XomaZyme-CD5 Plus) could ameliorate symptoms of GVHD. In a randomized, double-blind trial, we compared XomaZyme-CD5 Plus and glucocorticoids versus placebo and glucocorticoids as initial therapy for 243 patients who developed acute GVHD after allogeneic marrow transplantation. The study drug (XomaZyme. CD5-Plus or an identical appearing placebo) was administered at a dose of 0.1 mg/kg body weight on each of 14 consecutive days. All patients were treated concomitantly with a standard regimen of methylprednisolone. At the time of entry on study, 94% of patients had a rash, 56% had hyperbilirubinemia, 61% had diarrhea, and 84% had nausea and vomiting. At 3, 4, and 5 weeks after starting treatment, symptom severity was less in the CD5 group than in the placebo group. At 4 weeks, 40% of patients assigned to the CD5 group had complete response compared with 25% of those assigned to the control group (P = .019). At 6 weeks, 44% of patients assigned to the CD5 group had complete response as compared with 38% in the placebo group (P = .36). Clinical extensive chronic GVHD developed in 65% of patients in the CD5 group compared with 72% in the control group (P = .35). Survival at 1 year after treatment was 49% in the CD5 group and 45% in the control group (P = .68). Side effects required close monitoring and appropriate adjustment of treatment. The combined administration of a CD5-specific immunotoxin and glucocorticoids controls GVHD manifestations more effectively than treatment with glucocorticoids alone during the first 5 weeks after starting treatment. Use of this immunotoxin does not result in any long-term clinical benefit for patients with acute GVHD. 相似文献
995.
Liu P; Leong T; Quam L; Billadeau D; Kay NE; Greipp P; Kyle RA; Oken MM; Van Ness B 《Blood》1996,88(7):2699-2706
Mutations of members of the ras family are among the most common oncogene mutations found in multiple myeloma (MM). We have examined the mutational status of the N- and K-ras genes at codons 12, 13, and 61 in 160 newly diagnosed MM patients enrolled on the Eastern Cooperative Oncology Group (ECOG) phase III clinical trial E9486. The total incidence of ras mutations was found to be 39% of the samples analyzed. Five patients showed evidence of more than one mutation. We obtained 22 marrow samples from patients at the time of disease progression or relapse, for whom a ras mutation was identified at diagnosis. In all cases, the ras mutation of the disease progression sample was identical to that found at diagnosis. In contrast, three of 25 patients who did not show any ras mutation at diagnosis acquired a ras mutation at the time of disease progression. No significant association was observed between any ras mutation and stage of disease, beta 2-microglobulin levels, labelling index, or protein type. The mean tumor burden and median survival for patients with mutations of N-ras was indistinguishable from patients with no ras mutations. However, patients with K-ras mutations had a significantly higher mean bone marrow tumor burden at diagnosis than patients with no ras mutations (57% v 36%, P < .02); and the median survival of patients with a K-ras mutation was significantly shorter (2.0 v 3.7 years, P < .02). To determine if the status of ras mutations could affect treatment response, we examined patient survival on the three treatment arms of E9486. Although the presence of a ras mutation in the multidrug treatment, VBMCP alone, showed a marginal significance, neither the VBMCP, nor the addition of interferon-alpha showed statistically significant survival differences between mutant and wildtype ras status. Interestingly, there appeared to be a statistically significant difference in survival of patients treated with VBMCP and alternating high doses of cyclophosphamide + prednisone. Patients with ras mutations had a median survival of 2.1 years; patients with wild-type ras had a median survival of 4.0 years (P < .01). 相似文献
996.
997.
Short remission durations in therapy-related leukemia despite cytogenetic complete responses to high-dose cytarabine 总被引:1,自引:1,他引:1
Larson RA; Wernli M; Le Beau MM; Daly KM; Pape LH; Rowley JD; Vardiman JW 《Blood》1988,72(4):1333-1339
Seventeen patients with therapy-related myelodysplastic syndrome (t- MDS) or therapy-related acute nonlymphocytic leukemia (t-ANLL) were treated with single-agent high-dose cytarabine (HDAC; 1 to 3 g/m2 every 12 hours for 12 doses). The initial neoplasm was still present in eight patients when t-MDS/t-ANLL developed. Fifteen of the 16 patients with chromosomal abnormalities in bone marrow cells had loss or rearrangement of chromosomes 5 and/or 7. One patient had a t(15;17), and one had inadequate material for cytogenetic analysis. Twelve patients had normal metaphase cells (3% to 71%). Indications for HDAC therapy were progressive pancytopenia in 13 patients or rising blast count in four. Five patients died of marrow hypoplasia following therapy. Four others had refractory t-ANLL and died within the subsequent 5 months. Only one of ten patients with a poor performance status (PS greater than or equal to 2 using the ECOG scale) achieved a complete remission, but all seven patients with a good performance status (PS less than or equal to 1) had a complete remission. Hematologic remissions were achieved in 8 patients (47%) after one (6 patients) or two (2 patients) induction courses and were confirmed by recovery of a 100% normal marrow karyotype in six of the seven patients who were retested. Patients in remission received one to four consolidation courses with HDAC alternating with cytarabine/doxorubicin, but seven relapsed within 8 months (median remission duration, 5 months). In every case, the original chromosomal abnormality reappeared at relapse. HDAC has a high response rate for good-performance patients with t-MDS/t-ANLL, but complete remissions are short even when confirmed cytogenetically and consolidated intensively. 相似文献
998.
A neutrophil membrane marker reveals two groups of chronic myelogenous leukemia and its absence may be a marker of disease progression 总被引:1,自引:0,他引:1
Gallin JI; Jacobson RJ; Seligmann BE; Metcalf JA; McKay JH; Sacher RA; Malech HL 《Blood》1986,68(2):343-346
An IgG1 monoclonal antibody, 31D8, that recognizes normal neutrophil (PMN) membranes, was used to study PMN from patients with chronic myelogenous leukemia (CML). Nineteen patients with Philadelphia chromosome positive CML were followed over a ten-month period and compared with 23 normals, six patients with leukemoid reactions, and eight patients with phagocytic cell defects. The percentage of PMN binding of 31D8 among normal subjects was variable about a normal distribution with an average of 95 +/- 2% of cells binding 31D8. In contrast, there were two groups of CML patients: in 14 patients 88 +/- 3% PMN bound 31D8 while in the remaining five patients only 6 +/- 6% PMN bound 31D8. PMN 31D8 binding was normal in the control patient groups. Control antibodies 7C3 (binds to PMN precursors) and OKM1 (binds to the CR3 (iC3b) receptor) bound normally to CML neutrophils. Functionally, CML cells had normal chemotaxis to several stimuli and normal superoxide generation to phorbol myristate acetate. However, superoxide production in response to fmet-leu-phe was significantly less in 31D8 negative CML PMN than both 31D8 positive CML PMN and normal PMN which contained 85% 31D8 positive and 15% 31D8 negative PMN. Clinically, 2 of 14 CML patients with 31D8 positive PMN were in blast crisis (one extramedullary) at the time of study and the other 12 patients remained clinically stable in the chronic phase during the ten months of study. In contrast, one of five patients with 31D8 negative PMN was in blast crisis at the time of study and all four of the remaining patients progressed to either the accelerated phase or blast crisis. Three of these patients died of their disease eight to ten months after their initial study. Thus, failure of CML cells to bind 31D8 may be useful for predicting which patients are likely to progress to the accelerated phase or blast crisis. 相似文献
999.
Lymphomagenesis in the SCID-hu mouse involves abundant production of human interleukin-10 总被引:6,自引:1,他引:6
1000.
Retarded recovery of functional T cell frequencies in T cell-depleted bone marrow transplant recipients 总被引:3,自引:1,他引:3
We have studied the effect of removing donor T cells by treatment with the monoclonal antibody Leu-1 and complement before marrow transplantation on the regeneration of functionally competent T lymphocytes in the blood at selected times after transplant. Using sensitive limiting-dilution methods that allow us to enumerate helper, cytotoxic, and proliferating T lymphocyte precursors, we report that regeneration of a functional T cell compartment is more severely impaired for the first 180 days after transplantation in those patients given T cell-depleted bone marrow than in recipients of untreated marrow. After this first 6 months, however, patients given T cell- depleted bone marrow had blood T cell frequencies comparable to those observed in patients given untreated marrow. Diminished frequencies of reactive T cells in recipients of depleted marrow could leave them more susceptible to infection or to the recurrence of neoplastic cells. 相似文献